Yarrow Bioscience, Inc. Common Stock
YARW
37 hedge funds and large institutions have $3.25M invested in Yarrow Bioscience, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 8 closing their positions.
0% less ownership
Funds ownership: 0.02% → 0.02% (-0%)
10% less funds holding
Funds holding: 41 → 37 (-4)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
40% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 10
42% less capital invested
Capital invested by funds: $5.63M → $3.25M (-$2.38M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$150K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$59.6K |
| 3 |
CAN
Cetera Advisor Networks
El Segundo,
California
|
+$53.7K |
| 4 |
VF
Virtu Financial
New York
|
+$18.9K |
| 5 |
Citigroup
New York
|
+$18K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$154K |
| 2 |
B
Bailard
Foster City,
California
|
-$91K |
| 3 |
Millennium Management
New York
|
-$88.1K |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$65K |
| 5 |
BlackRock
New York
|
-$52.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
LPL Financial
San Diego,
California
| $7K | -$419 | -1 | -5% |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| $5K | +$2.1K | +5 | +63% |
|
|
TFA
28
Tobias Financial Advisors
Plantation,
Florida
| $4K | – | – | – |
|
29
UBS Group
Zurich,
Switzerland
| $4K | +$5.03K | +12 | New |
|
30
Federated Hermes
Pittsburgh,
Pennsylvania
| $1K | – | – | – |
|
31
Russell Investments Group
London,
United Kingdom
| $1K | – | – | – |
|
|
CS
32
Credit Suisse
Zurich,
Switzerland
| $1K | +$1.26K | +3 | New |
|
|
GCP
33
GSA Capital Partners
London,
United Kingdom
| – | -$154K | -263 | Closed |
|
|
B
34
Bailard
Foster City,
California
| – | -$91K | -155 | Closed |
|
|
35
Baillie Gifford & Co
Edinburgh,
United Kingdom
| – | -$65K | -110 | Closed |
|
36
Citadel Advisors
Miami,
Florida
| – | -$20.8K | -50 | Closed |
|
|
HF
37
HRT Financial
New York
| – | -$10K | -18 | Closed |
|
38
Jane Street
New York
| – | -$8K | -13 | Closed |
|
39
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$7K | -11 | Closed |
|
40
JP Morgan Chase
New York
| – | -$2.52K | -6 | Closed |
|
41
Rockefeller Capital Management
New York
| – | +$419 | +1 | +100% |
|
YARW Hedge Fund Activity: Q2 2022 in Review
37 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Yarrow Bioscience, Inc. Common Stock (YARW) for Q2 2022, worth a combined $3.25M — down 42% from $5.63M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of YARW and 5 opened new positions — a net loss of 3 holders — while 10 trimmed existing stakes and 6 added.
The largest buyer was Vanguard Group, adding an estimated $150K. The largest seller was GSA Capital Partners, exiting entirely with an estimated $154K sold.
- 37 institutional investors held Yarrow Bioscience, Inc. Common Stock (YARW) as of Q2 2022, down from 41 in Q1 2022.
- Funds reported $3.25M of Yarrow Bioscience, Inc. Common Stock stock for Q2 2022, down 42% quarter-over-quarter.
- 5 funds opened new Yarrow Bioscience, Inc. Common Stock positions in Q2 2022 and 8 closed out, a net change of -3 holders.
- The largest Yarrow Bioscience, Inc. Common Stock buyer in Q2 2022 was Vanguard Group, an estimated $150K added.
- The largest Yarrow Bioscience, Inc. Common Stock seller in Q2 2022 was GSA Capital Partners, an estimated $154K sold.
Based on aggregated 13F filings for Q2 2022.